Trial Profile
A Study to Evaluate the Effect of BTI320 (SUGARDOWN®) on Post-Prandial Hyperglycaemia in High Risk Chinese Subjects With Pre-Diabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs BTI 320 (Primary)
- Indications Prediabetic state
- Focus Proof of concept; Therapeutic Use
- Sponsors Advance Pharmaceutical Co Ltd
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
- 13 Oct 2016 Status changed from active, no longer recruiting to completed, as reported in a Boston Therapeutics media release.
- 06 Oct 2016 According to a Boston Therapeutics media release, abbreviated description of this clinical trial was presented at the seminar for "Frontier Technologies with Impact in Public Health" at the Chinese University of Hong Kong.